Drug Type Small molecule drug |
Synonyms Ibuprofen/Diphenhydramine Hydrochloride, 复方布洛芬缓释片(越洋医药) + [1] |
Target |
Action inhibitors, inverse agonists |
Mechanism COX inhibitors(Cyclooxygenases inhibitors), H1 receptor inverse agonists(Histamine H1 receptor inverse agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (21 Dec 2005), |
Regulation- |
Molecular FormulaC13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS Registry15687-27-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | United States | 21 Dec 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain | Phase 1 | China | 28 Nov 2022 | |
Sleep Initiation and Maintenance Disorders | Phase 1 | China | 28 Nov 2022 |
Phase 1 | 77 | Advil PM Liqui-Gels+ibuprofen+diphenhydramine hydrochloride (Treatment A (Test)) | fythwzuhzr(ctpqsbrrtf) = ctwzbefofc dlmngzzxvq (fsxkidolkc, myysnpjylr - nezkrvfyix) View more | - | 23 Aug 2024 | ||
Advil PM Liqui-Gels+ibuprofen+diphenhydramine hydrochloride (Treatment B (Reference)) | fythwzuhzr(ctpqsbrrtf) = yrcnmscfyp dlmngzzxvq (fsxkidolkc, dzrnjdefoe - slqpaagegm) View more |